Benralizumab, mepolizumab and omalizumab for treating severe asthma

Respiratory

1 September 2020

Published on 01 Sep 2020
Last Updated on 01 Sep 2020

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing:

Benralizumab and mepolizumab on the Medication Assistance Fund (MAF) for treating severe eosinophilic asthma; and
Omalizumab on the MAF for treating severe allergic asthma

due to unacceptable cost-effectiveness at the prices proposed by the manufacturers.